Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 6Nausea 6Breast Neoplasms 3Neoplasms 2Hematologic Neoplasms 2Weight Loss 1Sedentary Behavior 1Postoperative Nausea and Vomiting 1Neoplasms, Plasma Cell 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Delirium 1Child Nutrition Disorders 1Cachexia 1Anorexia 1Advanced Cancer 1

Interventions

Dexamethasone 3Acupuncture Therapy 2ramosetron 1phenazine 1esmolol 1Therapeutics 1Surveys and Questionnaires 1Promethazine 1Ondansetron 1Olanzapine 1Fentanyl 1Famotidine 1Electric Stimulation Therapy 1Electric Stimulation 1Diphenhydramine 1Dexmedetomidine 1Calcium Dobesilate 1Antiemetics 1Anesthesia, General 1Analgesics, Opioid 1Adrenergic beta-Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Postoperative Nausea and Vomiting × Olanzapine × Clear all
NCT03631004 2022-01-13

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Instituto do Cancer do Estado de São Paulo

Phase 2/3 Completed
100 enrolled

Nausea, Vomiting, Postoperative Nausea and Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡